Posted On: 01/05/2015 5:03:13 PM
Post# of 9144
Re: nmbr1stckpckr #1190
"In this scenario involving capturing only 20 % of the US Group B Strep (GBS) market of 5 million tests annually, the total gross revenues are $200 million, production and operating costs $42.5 million and net revenues $157.5 million."
Nanologix represents less than 1% of the companies competing in this market place yet you think it's logical to assume they'd capture 20% of the market? Smh. What's sad is that some people actually believe that.
Industry stats show that this sector only produces a 16.7% net margin, but Mach calculated a 21.25% margin for Nanologix even though they have so many expenditures that they've never made a profit and their products are expensive to produce. Makes no sense.
Nanologix represents less than 1% of the companies competing in this market place yet you think it's logical to assume they'd capture 20% of the market? Smh. What's sad is that some people actually believe that.
Industry stats show that this sector only produces a 16.7% net margin, but Mach calculated a 21.25% margin for Nanologix even though they have so many expenditures that they've never made a profit and their products are expensive to produce. Makes no sense.
(0)
(0)
